Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients
Henrik Wagner(Örebro University Hospital), David Erlinge(Lund University), Dominick J. Angiolillo(University of Florida), Stefan James(Uppsala University), Patricia Brown(Eli Lilly (United States)), Chunmei Zhou(Eli Lilly (United States)), Thomas O. Bergmeijer(St. Antonius Ziekenhuis), Kenneth J. Winters(Eli Lilly (United States)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Jurriën M. ten Berg(St. Antonius Ziekenhuis), David S. Small(Eli Lilly (United States)), Brian A. Moser(Eli Lilly (United States))
Cited by 30
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
|New England Journal of Medicine|2013|2.8k